{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:09:02Z","timestamp":1791918542808,"version":"4.3.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/bjc.2017.69","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T19:45:58Z","timestamp":1489693558000},"page":"1119-1125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach"],"prefix":"10.1038","volume":"116","author":[{"given":"Maria J","family":"Bueno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Mouron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Quintela-Fandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"issue":"6","key":"BFbjc201769_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.celrep.2016.04.029","volume":"15","author":"E Allen","year":"2016","unstructured":"Allen E, Mieville P, Warren CM, Saghafinia S, Li L, Peng MW, Hanahan D (2016) Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep 15 (6): 1144\u20131160.","journal-title":"Cell Rep"},{"issue":"19","key":"BFbjc201769_CR2","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Geczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, Investigators M (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (19): 1814\u20131823.","journal-title":"N Engl J Med"},{"issue":"1","key":"BFbjc201769_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2011.11.024","volume":"21","author":"VG Cooke","year":"2012","unstructured":"Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, Sugimoto H, Rocha RM, Damascena A, Brentani RR, Kalluri R (2012) Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21 (1): 66\u201381.","journal-title":"Cancer Cell"},{"issue":"7503","key":"BFbjc201769_CR4","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","volume":"330","author":"JM Evans","year":"2005","unstructured":"Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330 (7503): 1304\u20131305.","journal-title":"BMJ"},{"issue":"21","key":"BFbjc201769_CR5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (21): 1182\u20131186.","journal-title":"N Engl J Med"},{"issue":"1","key":"BFbjc201769_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","volume":"82","author":"J Folkman","year":"1990","unstructured":"Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 (1): 4\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"BFbjc201769_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","volume":"20","author":"M Foretz","year":"2014","unstructured":"Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B (2014) Metformin: from mechanisms of action to therapies. Cell Metab 20 (6): 953\u2013966.","journal-title":"Cell Metab"},{"issue":"5","key":"BFbjc201769_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.molonc.2015.12.011","volume":"10","author":"E Hernandez-Agudo","year":"2016","unstructured":"Hernandez-Agudo E, Mondejar T, Soto-Montenegro ML, Megias D, Mouron S, Sanchez J, Hidalgo M, Lopez-Casas PP, Mulero F, Desco M, Quintela-Fandino M (2016) Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET. Mol Oncol 10 (5): 704\u2013718.","journal-title":"Mol Oncol"},{"issue":"43","key":"BFbjc201769_CR9","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 109 (43): 17561\u201317566.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"BFbjc201769_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (23): 2335\u20132342.","journal-title":"N Engl J Med"},{"issue":"17","key":"BFbjc201769_CR11","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","volume":"31","author":"RK Jain","year":"2013","unstructured":"Jain RK (2013) Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31 (17): 2205\u20132218.","journal-title":"J Clin Oncol"},{"issue":"6","key":"BFbjc201769_CR12","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.celrep.2016.04.015","volume":"15","author":"G Jimenez-Valerio","year":"2016","unstructured":"Jimenez-Valerio G, Martinez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suarez C, Garcia-Del-Muro X, Carles J, Vinals F, Graupera M, Indraccolo S, Casanovas O (2016) Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients. Cell Rep 15 (6): 1134\u20131143.","journal-title":"Cell Rep"},{"issue":"7","key":"BFbjc201769_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1470-2045(15)00027-3","volume":"16","author":"S Kordes","year":"2015","unstructured":"Kordes S, Pollak MN, Zwinderman AH, Mathot RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW (2015) Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 16 (7): 839\u2013847.","journal-title":"Lancet Oncol"},{"issue":"7","key":"BFbjc201769_CR14","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1158\/0008-5472.CAN-06-3312","volume":"67","author":"SM Kumar","year":"2007","unstructured":"Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X (2007) Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res 67 (7): 3177\u20133184.","journal-title":"Cancer Res"},{"issue":"4","key":"BFbjc201769_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/imm.12380","volume":"143","author":"V Kumar","year":"2014","unstructured":"Kumar V, Gabrilovich DI (2014) Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology 143 (4): 512\u2013519.","journal-title":"Immunology"},{"issue":"20","key":"BFbjc201769_CR16","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.1158\/1078-0432.CCR-12-0552","volume":"18","author":"LP Liu","year":"2012","unstructured":"Liu LP, Ho RL, Chen GG, Lai PB (2012) Sorafenib inhibits hypoxia-inducible factor-1alpha synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res 18 (20): 5662\u20135671.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"BFbjc201769_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccr.2012.05.037","volume":"22","author":"KV Lu","year":"2012","unstructured":"Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET\/VEGFR2 complex. Cancer Cell 22 (1): 21\u201335.","journal-title":"Cancer Cell"},{"key":"BFbjc201769_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-cellbio-092910-154237","volume":"27","author":"SY Lunt","year":"2011","unstructured":"Lunt SY, Vander Heiden MG (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27: 441\u2013464.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"15","key":"BFbjc201769_CR19","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.4161\/cc.10.15.16585","volume":"10","author":"UE Martinez-Outschoorn","year":"2011","unstructured":"Martinez-Outschoorn UE, Lin Z, Trimmer C, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP (2011) Cancer cells metabolically \u2018fertilize\u2019 the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle 10 (15): 2504\u20132520.","journal-title":"Cell Cycle"},{"issue":"20","key":"BFbjc201769_CR20","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.1158\/0008-5472.CAN-11-2025","volume":"71","author":"S Matsumoto","year":"2011","unstructured":"Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, Gadisetti C, Subramanian S, Devasahayam N, Munasinghe JP, Mitchell JB, Krishna MC (2011) Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 71 (20): 6350\u20136359.","journal-title":"Cancer Res"},{"issue":"8","key":"BFbjc201769_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","volume":"15","author":"BJ Monk","year":"2014","unstructured":"Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhomme C, Richardson G, Rincon DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM (2014) Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15 (8): 799\u2013808.","journal-title":"Lancet Oncol"},{"issue":"15","key":"BFbjc201769_CR22","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16 (15): 1473\u20131482.","journal-title":"Lancet Oncol"},{"issue":"5","key":"BFbjc201769_CR23","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.2353\/ajpath.2006.050711","volume":"169","author":"DA Murphy","year":"2006","unstructured":"Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM (2006) Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 169 (5): 1875\u20131885.","journal-title":"Am J Pathol"},{"issue":"12","key":"BFbjc201769_CR24","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.celrep.2016.05.052","volume":"15","author":"P Navarro","year":"2016","unstructured":"Navarro P, Bueno MJ, Zagorac I, Mondejar T, Sanchez J, Mouron S, Munoz J, Gomez-Lopez G, Jimenez-Renard V, Mulero F, Chandel NS, Quintela-Fandino M (2016) Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics. Cell Rep 15 (12): 2705\u20132718.","journal-title":"Cell Rep"},{"issue":"5","key":"BFbjc201769_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ccr.2004.09.030","volume":"6","author":"J Oliner","year":"2004","unstructured":"Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, Rosenfeld R, Davy E, Graham K, Jacobsen F, Stevenson S, Ho J, Chen Q, Hartmann T, Michaels M, Kelley M, Li L, Sitney K, Martin F, Sun JR, Zhang N, Lu J, Estrada J, Kumar R, Coxon A, Kaufman S, Pretorius J, Scully S, Cattley R, Payton M, Coats S, Nguyen L, Desilva B, Ndifor A, Hayward I, Radinsky R, Boone T, Kendall R (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6 (5): 507\u2013516.","journal-title":"Cancer Cell"},{"issue":"4","key":"BFbjc201769_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.immuni.2014.09.008","volume":"41","author":"A Palazon","year":"2014","unstructured":"Palazon A, Goldrath AW, Nizet V, Johnson RS (2014) HIF transcription factors, inflammation, and immunity. Immunity 41 (4): 518\u2013528.","journal-title":"Immunity"},{"issue":"23","key":"BFbjc201769_CR27","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.4161\/cc.8.23.10238","volume":"8","author":"S Pavlides","year":"2009","unstructured":"Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP (2009) The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8 (23): 3984\u20134001.","journal-title":"Cell Cycle"},{"issue":"2","key":"BFbjc201769_CR28","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/0006-291X(92)92277-5","volume":"189","author":"MS Pepper","year":"1992","unstructured":"Pepper MS, Ferrara N, Orci L, Montesano R (1992) Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189 (2): 824\u2013831.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"BFbjc201769_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.celrep.2016.04.028","volume":"15","author":"L Pisarsky","year":"2016","unstructured":"Pisarsky L, Bill R, Fagiani E, Dimeloe S, Goosen RW, Hagmann J, Hess C, Christofori G (2016) Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. Cell Rep 15 (6): 1161\u20131174.","journal-title":"Cell Rep"},{"issue":"6","key":"BFbjc201769_CR30","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1158\/1078-0432.CCR-16-0738","volume":"23","author":"Miguel Quintela-Fandino","year":"2016","unstructured":"Quintela-Fandino M, Lluch A, Manso LM, Calvo I, Cortes J, Garcia-Saenz JA, Gil JM, Martinez-Janez N, Gonzalez-Martin A, Adrover E, De Andres R, Vinas G, Llombart Cussac A, Alba E, Guerra J, Bermejo B, Zamora E, Moreno-Anton F, Pernas-Simon S, Carrato A, Lopez A, Escudero MJ, Campo R, Carrasco EM, Palacios J, Mulero F, Colomer R (2016) 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: a window-of-opportunity randomized trial. Clin Cancer Res e-pub ahead of print 1 September 2016 doi:10.1158\/1078-0432.CCR-16-0738.","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"BFbjc201769_CR31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nrc3366","volume":"12","author":"B Sennino","year":"2012","unstructured":"Sennino B, McDonald DM (2012) Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 12 (10): 699\u2013709.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"BFbjc201769_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/bdd.684","volume":"30","author":"Y Sogame","year":"2009","unstructured":"Sogame Y, Kitamura A, Yabuki M, Komuro S (2009) A comparison of uptake of metformin and phenformin mediated by hOCT1 in human hepatocytes. Biopharm Drug Dispos 30 (8): 476\u2013484.","journal-title":"Biopharm Drug Dispos"},{"issue":"12","key":"BFbjc201769_CR33","first-page":"3930","volume":"118","author":"P Sonveaux","year":"2008","unstructured":"Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118 (12): 3930\u20133942.","journal-title":"J Clin Invest"},{"issue":"1","key":"BFbjc201769_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","volume":"21","author":"AA Van der Veldt","year":"2012","unstructured":"Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serne EH, Lammertsma AA, Smit EF (2012) Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21 (1): 82\u201391.","journal-title":"Cancer Cell"},{"issue":"11","key":"BFbjc201769_CR35","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.4161\/cc.10.11.15659","volume":"10","author":"D Whitaker-Menezes","year":"2011","unstructured":"Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, Birbe RC, Howell A, Pavlides S, Gandara R, Pestell RG, Sotgia F, Philp NJ, Lisanti MP (2011) Evidence for a stromal-epithelial \u2018lactate shuttle\u2019 in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 10 (11): 1772\u20131783.","journal-title":"Cell Cycle"},{"issue":"45","key":"BFbjc201769_CR36","doi-asserted-by":"publisher","first-page":"18226","DOI":"10.1073\/pnas.1317577110","volume":"110","author":"P Yuan","year":"2013","unstructured":"Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC, Zheng B (2013) Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci USA 110 (45): 18226\u201318231.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201769.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201769","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.69","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201769.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T09:41:35Z","timestamp":1684402895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFbjc201769"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.69","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]},"assertion":[{"value":"17 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}